...
首页> 外文期刊>Journal of oral pathology and medicine: Official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology >HER family receptors expression in squamous cell carcinoma of the tongue: study of the possible prognostic and biological significance.
【24h】

HER family receptors expression in squamous cell carcinoma of the tongue: study of the possible prognostic and biological significance.

机译:HER家族受体在舌鳞状细胞癌中的表达:对可能的预后和生物学意义的研究。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: The squamous cell carcinoma of the tongue (SCCT) is biologically and epidemiologically distinct from other oral cavity cancers and is associated with lower overall survival rates. The role of HER family members (HER-1, HER-2eu, HER-3 and HER-4) in the pathogenesis and progression of head and neck squamous cell carcinomas has been demonstrated but no report have focused on SCCT. This study investigated, the expression of all members of the HER family, in a series of SCCT and studied the possible prognostic value and correlation with various clinico-pathological parameters. METHODS: HER-1, HER-2eu, HER-3 and HER-4 expression was analysed by semi-quantitative immunohistochemical staining on paraffin embedded tissue specimens from 40 patients who underwent surgery for SCCT between 1996 and 2006. RESULTS: HER-1 was overexpressed in 26 cases (65%), HER-2eu in two (5%), HER-3 in 19 (48%) and HER-4 in three cases (8%). No significant correlation was found between clinicopathological variables and expression of HER-1 and HER-2eu. HER-3 overexpression was significantly related to nodal stage, age (>or=64 years) and decreased overall survival (P
机译:目的:舌鳞状细胞癌(SCCT)在生物学和流行病学上与其他口腔癌不同,并且与较低的总生存率有关。已经证明了HER家族成员(HER-1,HER-2 / neu,HER-3和HER-4)在头颈部鳞状细胞癌的发病机理和进展中的作用,但是尚无关于SCCT的报道。这项研究调查了一系列SCCT中HER家族所有成员的表达,并研究了可能的预后价值以及与各种临床病理参数的相关性。方法:对1996年至2006年间行SCCT手术的40例石蜡包埋组织标本进行半定量免疫组织化学染色,分析了HER-1,HER-2 / neu,HER-3和HER-4的表达。结果:HER- 1例在26例(65%)中过表达,HER-2 / neu在2例(5%)中,HER-3在19例中(48%),HER-4在3例中(8%)。在临床病理变量与HER-1和HER-2 / neu的表达之间未发现显着相关性。 HER-3过表达与淋巴结分期,年龄(≥64岁)和总生存期降低(P≤0.05)显着相关。 HER-4过表达与低组织学分级显着相关,包括与HER-3共表达时,但在这种情况下预后较差(P <0.05)。结论:这些结果表明,以严格的标准确定HER-1和HER-2 / neu并不是SCCT预后的有用指标。当它与HER-4共表达时,只有HER-3过表达可能有助于鉴定具有更大恶性潜能的SCCT。相反,与其他恶性肿瘤一样,HER-4可能在SCCT中起保护作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号